Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
ETF Actively managed strategy
TER
0.75% p.a.
Distribution policy
Accumulating
Replication
Physical
Fund size
EUR 41 m
Inception Date
12 April 2024
Holdings
35
Overview
Description
The ARK Genomic Revolution UCITS ETF USD Accumulating is an actively managed ETF.
The ETF invests in companies from around the world that are expected to derive revenue from technological innovations in the genomic healthcare sector. The stocks included are filtered according to ESG criteria (environmental, social and corporate governance).
Documents
Chart
Basics
Data
| Index | ARK Genomic Revolution |
| Investment focus | Equity, World, Health Care |
| Fund size | EUR 41 m |
| Total expense ratio | 0.75% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Actively managed |
| Sustainability | Yes |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 41.00% |
| Inception/ Listing Date | 12 April 2024 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | ARK Invest International |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | Northern Trust International Fund Administration Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | Northern Trust Fiduciary Services (Ireland) Limited |
| Revision Company | Deloitte Ireland LLP |
| Fiscal Year End | 1 June |
| Swiss representative | 1741 Fund Solutions AG |
| Swiss paying agent | Tellco AG |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | - |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
Similar ETFs
This section provides you with information on other ETFs with a similar investment focus to the ARK Genomic Revolution UCITS ETF USD Accumulating.
Similar ETFs via ETF search
Similar ETFs via investment guides
How do you like our ETF profile? Here you'll find our Questionnaire.
Holdings
Below you find information about the composition of the ARK Genomic Revolution UCITS ETF USD Accumulating.
Top 10 Holdings
Weight of top 10 holdings
out of 35
58.50%
| Twist Bioscience | 8.85% |
| CRISPR Therapeutics | 8.80% |
| Tempus AI, Inc. | 7.85% |
| Beam Therapeutics | 6.50% |
| Personalis | 5.28% |
| 10x Genomics | 4.83% |
| Natera | 4.24% |
| Intellia Therapeutics | 4.18% |
| Illumina, Inc. | 4.13% |
| Recursion Pharmaceuticals | 3.84% |
Countries
| United States | 76.11% |
| Switzerland | 8.80% |
| United Kingdom | 2.02% |
| Other | 13.07% |
Sectors
| Health Care | 85.74% |
| Technology | 1.19% |
| Other | 13.07% |
As of 25/02/2026
ETF Savings plan offers
Here you can find information about the savings plan availability of the ETF. You can use the table to compare all savings plan offers for the selected savings rate.
Select your savings amount:
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
 | 0.00 € | 0.00 € | View offer** | |
 | 0.00 € | 0.00 € | View offer* | |
 | 0.00 € | 0.00 € | View offer* | |
 | 0.00 € | 0.00 € | View offer* | |
 | 0.00 € | 0.00 € | View offer* |
Source: justETF Research; as of 4/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of ETF savings plans. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable GmbH. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable GmbH. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Order fees
Here you can find information about different brokers that allow you to trade ETFs. Select your preferred order volume to compare the fees charged by the respective brokers.
Order volume:
| Broker | Rating | Order fee | ETF savings plans | |
|---|---|---|---|---|
| | 0.99 € | 3138 | View offer** | |
| | 0.00 € | 2615 | View offer* | |
 | 0.00 € | 1871 | View offer* | |
 | 0.00 € | 2280 | View offer* | |
| | 1.00 € | 2634 | View offer* |
Source: justETF Research; as of 4/2026. The offers are sorted in the following way: 1. Rating 2. Order fee 3. Number of ETF savings plans. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable GmbH. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable GmbH. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Performance
Returns overview
| YTD | -6.49% |
| 1 month | -4.64% |
| 3 months | -12.02% |
| 6 months | -11.84% |
| 1 year | +33.33% |
| 3 years | - |
| 5 years | - |
| Since inception (MAX) | -4.42% |
| 2025 | +9.22% |
| 2024 | - |
| 2023 | - |
| 2022 | - |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 41.00% |
| Volatility 3 years | - |
| Volatility 5 years | - |
| Return per risk 1 year | 0.81 |
| Return per risk 3 years | - |
| Return per risk 5 years | - |
| Maximum drawdown 1 year | -25.87% |
| Maximum drawdown 3 years | - |
| Maximum drawdown 5 years | - |
| Maximum drawdown since inception | -41.54% |
Rolling 1 year volatility
Stock exchange
Listings
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| Borsa Italiana | EUR | ARKG | - - | - - | - |
| gettex | EUR | AAKG | - - | - - | - |
| London Stock Exchange | GBX | ARCG | |||
| London Stock Exchange | USD | ARKG | |||
| SIX Swiss Exchange | CHF | ARKG | |||
| XETRA | EUR | AAKG |
Further information
Further ETFs with similar investment focus
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 864 | 0.40% p.a. | Accumulating | Sampling |
| L&G Healthcare Technology & Innovation UCITS ETF USD Acc | 158 | 0.49% p.a. | Accumulating | Full replication |
| L&G Pharma Breakthrough UCITS ETF | 17 | 0.49% p.a. | Accumulating | Full replication |
| VanEck Genomics and Healthcare Innovators UCITS ETF A | 11 | 0.35% p.a. | Accumulating | Full replication |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 8 | 0.30% p.a. | Accumulating | Full replication |
Latest articles
Frequently asked questions
What is the name of AAKG?
The name of AAKG is ARK Genomic Revolution UCITS ETF USD Accumulating.
What is the ticker of ARK Genomic Revolution UCITS ETF USD Accumulating?
The primary ticker of ARK Genomic Revolution UCITS ETF USD Accumulating is AAKG.
What is the ISIN of ARK Genomic Revolution UCITS ETF USD Accumulating?
The ISIN of ARK Genomic Revolution UCITS ETF USD Accumulating is IE000O5M6XO1.
What are the costs of ARK Genomic Revolution UCITS ETF USD Accumulating?
The total expense ratio (TER) of ARK Genomic Revolution UCITS ETF USD Accumulating amounts to 0.75% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is ARK Genomic Revolution UCITS ETF USD Accumulating paying dividends?
ARK Genomic Revolution UCITS ETF USD Accumulating is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.
What's the fund size of ARK Genomic Revolution UCITS ETF USD Accumulating?
The fund size of ARK Genomic Revolution UCITS ETF USD Accumulating is 41m Euro. See the following article for more information about the size of ETFs.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.